B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome

Oncology

Volumn 66, Issue 5, 2004, Pages 411-419

  Deichmann, Martin ^a   Thome, Marianne ^a   Benner, Axel ^b   Näher, Helmut ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

B raf; Melanoma; Oncogene; Polymerase chain reaction; Single strand conformation polymorphism

Indexed keywords

RAF PROTEIN; RAS PROTEIN; TUMOR MARKER;

AMINO ACID SEQUENCE; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; EXON; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MELANOMA; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; RISK ASSESSMENT; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN CARCINOGENESIS; STATISTICAL ANALYSIS;

CLONING, MOLECULAR; ELECTROPHORESIS; EXONS; HUMANS; MELANOMA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 4444305039     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079490     Document Type: Article

References (50)

1. Brochez L, Naeyaert JM: Understanding the trends in melanoma incidence and mortality, where do we stand? Eur J Dermatol 2000;10:71-75.
2. Holstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in cancer. Science 1991;253:49-53.
3. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK: Mutation and expression of the p53 gene in human malignant melanomas. Melanoma Res 1994;4:35-45.
4. Zerp SF, van Elsas A, Peltenburg LT, Schrier PI: p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanogenesis. Br J Cancer 1999;79:921-926.
5. Haluska FG, Hodi FS: Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998;16:670-682.
6. Healy E, Sikkink S, Rees JL: Infrequent mutation of p16INK4 in sporadic melanoma. J Invest Dermatol 1996;107:318-321.
7. Wagner SN, Wagner C, Briedigkeit L, Goos M: Homozygous deletion of the p16INK4a and p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol 1998;138:13-21.
8. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N, Parsons R: The PTEN/MMAC1 tumour suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998;58:5667-5672.
9. Reifenberger J, Wolter M, Bostrom J, Buschges R, Schulte KW, Megahed M, Ruzicka T, Reifenberger G: Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch 2000;436:487-493.
10. Poetsch M, Dittberner T, Woenckhaus C: PTEN/MMAC1 in malignant melanoma and its importance for tumour progression. Cancer Genet Cytogenet 2001;125:21-26.
11. Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P: Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 2000;114:277-280.
12. Deichmann M, Thome M, Benner A, Egner U, Hartschuh W, Näher H: PTEN/MMAC1 expression in melanoma resection specimens. Br J Cancer 2002;87:1431-1436.
13. Tsao H, Zhang X, Benoit E, Haluska FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16:3397-3402.
14. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A: DMBT1 , a new member of the SRCR superfamily, on chromosome 10q25.3-q26.1 is deleted in malignant brain tumours. Nat Genet 1997;17:32-39.
15. Wu W, Kemp BL, Proctor ML, Gazdar AF, Minna JD, Hong WK, Mao L: Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 1999;59:1846-1851.
16. Deichmann M, Mollenhauer J, Helmke B, Thome M, Hartschuh W, Poustka A, Näher H: Analysis of losses of heterozygosity of the candidate tumour suppressor gene DMBT1 in uncultured malignant melanomas. Oncology 2002;63:166-172.
17. Serrone L, Hersey P: The chemoresistance of human malignant melanoma, an update. Melanoma Res 1999;9:51-58.
18. van't Veer LJ, Burgering BMT, Versteeg R, Boot AJM, Ruiter DJ, Osanto S, Schrier PI, Bos JL: N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;9:3114-3116.
19. Wagner SN, Ockenfels HM, Wagner C, Hofler H, Goos M: Ras gene mutations, a rare event in nonmetastatic primary malignant melanoma. J Invest Dermatol 1995;104:868-871.
20. Kraehn GM, Schartl M, Peter RU: Human malignant melanoma, a genetic disease? Cancer 1995;75:1228-1237.
21. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davies N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
22. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS: High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
23. Ruiz A, Antinolo G, Borrego S, Sánchez B, Sánchez J: PCR mutagenesis-based method for generation of positive controls for SSCP analysis. Biotechniques 1997;3:704-708.
24. Harrell FE: Regression Modeling Strategies, with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, Springer, 2001.
25. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, Wiley, 1989.
26. Harrell FE: Multiple missing value imputation by additive regression, bootstrapping, and predictive mean matching, unpublished.
27. Ihaka R, Gentleman RA: Language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
28. Daya-Grosjean L, Dumaz N, Sarasin A: The specificity of p53 mutation spectra in sunlight induced human cancers. J Photochem Photobiol B 1995;28:115-124.
29. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene, clues to cancer etiology and molecularpathogenesis. CancerRes1994;54:4855-4878.
30. Moles UP, Moyret C, Guillot B, Jeanteur P, Guilhou JJ, Theillet C, Basset-Seguin N: p53 gene mutations in human epithelial skin cancers. Oncogene 1993;8:583-588.
31. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE: Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993;90:4216-4220.
32. Peyssonnaux C, Eychène A: The Raf/MEK/ERK pathway, new concepts of activation. Biol Cell 2001;93:53-62.
33. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA: Essential role for oncogenic Ras in tumor maintenance. Nature 1999;400:468-472.
34. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U: N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998;111:757-761.
35. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149:739-744.
36. Barnier JV, Papin C, Eychène A, Lecoq O, Calothy G: The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem 1995;270:23381-23389.
37. Eychène A, Barnier JV, Dezelee P, Marx M, Laugier D, Calogeraki I, Calothy G: Quail neuroretina c-Rmil (B-raf) proto-oncogene cDNAs encode two proteins of 93.5 and 95 kDa resulting from alternative splicing. Oncogene 1992;7:1315-1323.
38. Marx M, Eychène A, Laugier D, Bechade C, Crisanti P, Dezelee P, Pessac B, Calothy G: A novel oncogene related to c-mil is transduced in chicken neuroretina cells induced to proliferate by infection with an avian lymphomatosis virus. EMBO J 1988;11:3369-3373.
39. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
40. Halaban R: The regulation of normal melanocyte proliferation. Pigment Cell Res 2000;13:4-14.
41. Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, Ortonne JP, Ballotti R: Ras mediates the cDMAP-dependent activation of extracellular signal-related kinases (ERKs) in melanocytes. EMBO J 2000;19:2900-2910.
42. Englaro W, Rezzonico R, Durand-Clément M, Lallemand D, Ortonne JP, Ballotti R: Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J Biol Chem 1995;270:24315-24320.
43. Imokawa G, Yada Y, Miyagishi M: Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 1992;267:24675-24680.
44. Yada Y, Higuchi K, Imokawa G: Effects of endothelins on signal transduction and proliferation in human melanocytes. J Biol Chem 1991;266:18352-18357.
45. Imokawa G, Yada Y, Kimura M: Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochem J 1996;314:305-312.
46. Swope VB, Medrano EE, Smalara D, Abdel-Malek-ZA: Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp Cell Res 1995;217:453-459.
47. Imokawa G, Kobayasi T, Miyagishi M: Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes, cross-talk via trans-activation of the tyrosine kinase c-kit receptor. J Biol Chem 2000;275:33321-33328.
48. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632.
49. Kelemen BR, Hsiao K, Goueli SA: Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 2002;277:8741-8748.
50. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883-3885.